Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 554

1.

NMO-IgG predicts the outcome of recurrent optic neuritis.

Matiello M, Lennon VA, Jacob A, Pittock SJ, Lucchinetti CF, Wingerchuk DM, Weinshenker BG.

Neurology. 2008 Jun 3;70(23):2197-200. doi: 10.1212/01.wnl.0000303817.82134.da.

PMID:
18434643
2.

Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis.

Petzold A, Pittock S, Lennon V, Maggiore C, Weinshenker BG, Plant GT.

J Neurol Neurosurg Psychiatry. 2010 Jan;81(1):109-11. doi: 10.1136/jnnp.2008.146894.

PMID:
20019228
3.

Neuromyelitis optica IgG status in acute partial transverse myelitis.

Scott TF, Kassab SL, Pittock SJ.

Arch Neurol. 2006 Oct;63(10):1398-400.

PMID:
17030654
4.

Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis.

Weinshenker BG, Wingerchuk DM, Vukusic S, Linbo L, Pittock SJ, Lucchinetti CF, Lennon VA.

Ann Neurol. 2006 Mar;59(3):566-9.

PMID:
16453327
5.

Revised diagnostic criteria for neuromyelitis optica (NMO). Application in a series of suspected patients.

Saiz A, Zuliani L, Blanco Y, Tavolato B, Giometto B, Graus F; Spanish-Italian NMO Study Group..

J Neurol. 2007 Sep;254(9):1233-7.

PMID:
17401734
6.

Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders.

Banwell B, Tenembaum S, Lennon VA, Ursell E, Kennedy J, Bar-Or A, Weinshenker BG, Lucchinetti CF, Pittock SJ.

Neurology. 2008 Jan 29;70(5):344-52.

PMID:
18094334
7.

Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells.

Hinson SR, McKeon A, Fryer JP, Apiwattanakul M, Lennon VA, Pittock SJ.

Arch Neurol. 2009 Sep;66(9):1164-7. doi: 10.1001/archneurol.2009.188.

PMID:
19752309
8.

Neuromyelitis optica antibodies in patients with severe optic neuritis in China.

Lai C, Tian G, Takahashi T, Liu W, Yang L, Zhang X.

J Neuroophthalmol. 2011 Mar;31(1):16-9. doi: 10.1097/WNO.0b013e3181f8a693.

PMID:
21150455
9.

Neuromyelitis optica and non organ-specific autoimmunity.

Pittock SJ, Lennon VA, de Seze J, Vermersch P, Homburger HA, Wingerchuk DM, Lucchinetti CF, Zéphir H, Moder K, Weinshenker BG.

Arch Neurol. 2008 Jan;65(1):78-83. doi: 10.1001/archneurol.2007.17.

PMID:
18195142
10.

Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays.

McKeon A, Fryer JP, Apiwattanakul M, Lennon VA, Hinson SR, Kryzer TJ, Lucchinetti CF, Weinshenker BG, Wingerchuk DM, Shuster EA, Pittock SJ.

Arch Neurol. 2009 Sep;66(9):1134-8. doi: 10.1001/archneurol.2009.178.

PMID:
19752303
11.

Neuromyelitis optica (NMO) antibody positivity in patients with transverse myelitis and no visual manifestations.

Hamnik SE, Hacein-Bey L, Biller J, Gruener G, Jay W.

Semin Ophthalmol. 2008 May-Jun;23(3):191-200. doi: 10.1080/08820530802049921.

PMID:
18432545
12.

[Inflammation of the optic nerve: when it should be considered as neuromyelitis optica--the experience of the Department of Neurology at Hadassah Hospital].

Vaknin-Dembinsky A, Levin N, Raz N, Abramsky O, Karussis D, Brill L, Petrou P, Ovadia H.

Harefuah. 2013 Feb;152(2):101-5, 122. Hebrew.

PMID:
23513502
13.

Neuromyelitis optica positive antibodies confer a worse course in relapsing-neuromyelitis optica in Cuba and French West Indies.

Cabrera-Gómez JA, Bonnan M, González-Quevedo A, Saiz-Hinarejos A, Marignier R, Olindo S, Graus F, Smadja D, Merle H, Thomas L, Gómez-García A, Cabre P.

Mult Scler. 2009 Jul;15(7):828-33. doi: 10.1177/1352458509104585.

PMID:
19498017
14.

Neuromyelitis optica immunoglobulins as a marker of disease activity and response to therapy in patients with neuromyelitis optica.

Weinstock-Guttman B, Miller C, Yeh E, Stosic M, Umhauer M, Batra N, Munschauer F, Zivadinov R, Ramanathan M.

Mult Scler. 2008 Sep;14(8):1061-7. doi: 10.1177/1352458508092811.

PMID:
18573816
15.

Neuromyelitis optica-IgG in idiopathic inflammatory demyelinating disorders amongst Hong Kong Chinese.

Chan KH, Ramsden DB, Yu YL, Kwok KH, Chu AC, Ho PW, Kwan JS, Lee R, Lim E, Kung MH, Ho SL.

Eur J Neurol. 2009 Mar;16(3):310-6. doi: 10.1111/j.1468-1331.2008.02376.x.

PMID:
19138340
16.

NMO-IgG and Devic's neuromyelitis optica: a French experience.

Marignier R, De Sèze J, Vukusic S, Durand-Dubief F, Zéphir H, Vermersch P, Cabre P, Cavillon G, Honnorat J, Confavreux C.

Mult Scler. 2008 May;14(4):440-5. doi: 10.1177/1352458507084595.

PMID:
18208892
17.

Aquaporin-4 autoantibodies in a paraneoplastic context.

Pittock SJ, Lennon VA.

Arch Neurol. 2008 May;65(5):629-32. doi: 10.1001/archneur.65.5.629. Erratum in: Arch Neurol. 2008 Oct;65(10):1394.

PMID:
18474738
18.

Differential regulation of IgG-NMO autoantibodies on S100Beta protein and disability in relapsing neuromyelitis optica.

Robinson-Agramonte MA, Gonçalves CA, Portela LV, Saiz-Hinarejos A, Oses JP, Motta LS, Muller AP, Marquez Gonzalez ME, Souza DO.

Neuroimmunomodulation. 2010;17(3):177-9. doi: 10.1159/000258717. Erratum in: Neuroimmunomodulation. 2010;17(6):378. Portela, Valmor L [corrected to Portela, L. Valmor]; Oses, Pierre J [corrected to Oses, Jean Pierre]; Motta, Souza L [corrected to Motta, Luis Souza]; Gomes de Souza, Onofre D [corrected to Souza, Diogo Onofre].

PMID:
20134196
19.

Diagnosis and treatment of neuromyelitis optica.

Wingerchuk DM.

Neurologist. 2007 Jan;13(1):2-11. Review.

PMID:
17215722
20.

Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica.

Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, Nakamura M, Watanabe S, Ishii N, Itoyama Y.

Tohoku J Exp Med. 2006 Dec;210(4):307-13.

Supplemental Content

Support Center